MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Svoboda, Marek ^a,b   Sana, Jiri ^a,b   Fabian, Pavel ^a   Kocakova, Ilona ^a   Gombosova, Jana ^a   Nekvindova, Jana ^c   Radova, Lenka ^d   Vyzula, Rostislav ^a   Slaby, Ondrej ^a,b  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

5 fluorouracil; Capecitabine; microRNA; Neoadjuvant chemoradiotherapy; Prediction; Radiation; Rectal cancer; Thymidylate synthetase

Indexed keywords

CAPECITABINE; FLUOROURACIL; MICRORNA; MICRORNA 190B; MICRORNA 196B; MICRORNA 215; MICRORNA 29B; MICRORNA 450A; MICRORNA 450B; MICRORNA 99A; MICRORNA LET 7E; UNCLASSIFIED DRUG;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; RADIATION DOSE; RECTUM CANCER; RECTUM CARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; PILOT PROJECTS; RADIATION TOLERANCE; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; RNA, NEOPLASM; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 84869193544     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-195     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] 2010, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr, accessed on 29/07/2012.
2. Dusek L, Muzík J, Gelnarová E, Fínek J, Vyzula R, Abrahámová J. Cancer Incidence and Mortality in the Czech Republic. Klin Onkol 2010, 23:311-324.
3. Dusek L, Muzik J, Kubasek M, Koptikova J, Zaloudik J, Vyzula R. Epidemiology of Malignant Tumours in the Czech Republic [online] 2005, Masaryk University, Czech Republic, http://www.svod.cz. Version 7.0 [2007], ISSN 1802 - 8861.
4. Giovannucci E, Wu K. Cancers of the colon and rectum. Cancer. Epidemiology and Prevention 2006, Oxford University Press, New York, Schottenfeld D, Fraumeni J, 3.
5. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC (American Joint Committee on Cancer) Cancer Staging Manual: 6th edition 2002, Springer, New York.
6. Edge SB, Byrd DR, Compton CC, Fritéz AG, Greene FL, Trotli A. AJCC (American Joint Committee on Cancer) Cancer Staging Manual: 7th edition 2010, Springer, New York.
7. Greene FL, Stewart AK, Norton HJ. New tumor-node-metastatis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol 2004, 22:1778-1784. 10.1200/JCO.2004.07.015, 14769855.
8. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 2010, 59:1383-1388. 10.1136/gut.2010.211557, 20732912.
9. Komuro K, Tada M, Tamoto E, Kawakami A, Matsunaga A, Teramoto K, Shindoh G, Takada M, Murakawa K, Kanai M, Kobayashi N, Fujiwara Y, Nishimura N, Hamada J, Ishizu A, Ikeda H, Kondo S, Katoh H, Moriuchi T, Yoshiki T. Right- and Left-Sided Colorectal Cancers Display Distinct Expression Profiles and the Anatomical Stratification Allows a High Accuracy Prediction of Lymph Node Metastasis. J Surg Res 2005, 124:216-224. 10.1016/j.jss.2004.10.009, 15820251.
10. Rodriguez-Bigas MA, Hoff P, Crane CH, et al. Carcinoma of the Colon and Rectum. Hollan-Frei Cancer Medicine 2006, 1369-1391. BC Decker Inc, Hamilton (Ontario), Kufe DW, Bast RC, Hait WN, 7.
11. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, Quirke P, Schmoll HJ, Sebag-Montefiore D, Taylor I, Van Cutsem E, Van de Velde C, Cellini N, Latini P, . Scientific Committee Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009, 92:148-163. 10.1016/j.radonc.2009.06.027, 19595467, Scientific Committee.
12. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24(28):4620-4625. 10.1200/JCO.2006.06.7629, 17008704.
13. Engels B, Gevaert T, Sermeus A, De Ridder M. Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer. Front Oncol 2012, 2:47. 3360164, 22655273.
14. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994, 73:2680-2686. 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C, 8194005.
15. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 2012, 99:918-928. 10.1002/bjs.8702, 22362002.
16. Suárez J, Vera R, Balén E, Gómez M, Arias F, Lera JM, Herrera J, Zazpe C. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis 2008, 10:563-8. 10.1111/j.1463-1318.2007.01424.x, 18070184.
17. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009, 8:102. 10.1186/1476-4598-8-102, 2780389, 19912656.
18. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S, Pepe S. A Specific miRNA Signature Correlates with Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2012, 83(4):1113-1119. 10.1016/j.ijrobp.2011.09.030, 22172905.
19. Drebber U, Lay M, Wedemeyer I, Vallböhmer D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP, Odenthal M. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol 2011, 39:409-15.
20. Reimers M, Carey VJ. Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol 2006, 411:119-34.
21. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk - database: prediction of possible miRNA binding sites by " walking" the genes of 3 genomes. J Biomed Inform 2011, 44(5):839-847. 10.1016/j.jbi.2011.05.002, 21605702.
22. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010, 9:96. 10.1186/1476-4598-9-96, 2881118, 20433742.
23. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010, 9(8):2265-2275. 10.1158/1535-7163.MCT-10-0061, 20647341.
24. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Ørntoft TF, Andersen CL, Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008, 68(24):10094-104. 10.1158/0008-5472.CAN-08-1569, 2836584, 19074875.
25. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R, Slaby O. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012, in press.
26. Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, Burke S, Shroyer K, Ju J. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer 2011, 10(4):340-347. 10.1016/j.clcc.2011.06.002, 3390153, 21752725.
27. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007, 67(23):11111-11116. 10.1158/0008-5472.CAN-07-2858, 18056433.
28. Bandres E, Arias F, Guerrero D, Lopes I, Gonzalez-Huariz M, Dorronsoro MLG, Montes M, Monzon F, Torrea N, Armendariz P, Balen E, Viudez A, Asin G, Chicata V, Hernandez I, Eito C, Garcia-Foncillas J. Association between a specific miRNA signature and pathological response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) patients. J Clin Oncol 2012, 30(Suppl abstr):e14057. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96385.
29. Suwaki N, Klare K, Tarsounas M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin Cell Dev Biol 2011, 22:898-905. 10.1016/j.semcdb.2011.07.019, 21821141.
30. Connolly K, Mitter R, Muir M, Jodrell D, Guichard S. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother Pharmacol 2009, 64(2):307-316. 10.1007/s00280-008-0872-x, 19034449.
31. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, Svoboda M, Dolezelova H, Smrcka M, Vyzula R, Michalek J, Hajduch M, Slaby O. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 2011, 102(12):2186-2190. 10.1111/j.1349-7006.2011.02092.x, 21895872.